# Zenas BioPharma share price today (Zenas BioPharma, Inc., ZBIO)

> Zenas BioPharma, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. ZBIO · Healthcare · Biotechnology · data as of 4 November 2026. Page: https://www.sectoralpha.in/us/stocks/zbio

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $28.46 (−15.3% in a year)
- Revenue (Jun 2026): ₹0.0 B
- Profit (Jun 2026), incl. one-off: −₹0.1 B (one-off item, see below)
- ROE: −156%, FY25

Biggest thing to watch: the price has already been rising for 20 weeks, so timing is the risk more than the business. ## What is the Zenas BioPharma share price today? Zenas BioPharma, Inc.'s share price was $28.46 at the close on 4 November 2026. It has been rising for 20 weeks. That is 13.5% above its average price over the last 200 trading days. In the last 52 weeks it traded between $16 and $42, and at that close it sat 47% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 5 weeks running. Over the last 2.1 years the share price moved +50% while the S&P 500 moved +35%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 2 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Zenas BioPharma pay? Zenas BioPharma, Inc. pays no dividend. In the last 4 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Zenas BioPharma on? Zenas BioPharma is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Zenas BioPharma profitable? Zenas BioPharma, Inc. posted a net loss of ₹0.1 B in the Jun 2026 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY25 year was a loss of ₹0.4 B. That loss is 11,145.6% of the quarter's revenue. Read this profit with care: at −₹0.1 B it is bigger than the quarter's whole revenue of ₹0.0 B. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −7,765.9% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## How much revenue does Zenas BioPharma make, and is it growing? Zenas BioPharma, Inc. reported ₹0.0 B of revenue in the Jun 2026 quarter. Over 2 years it has grown −55.3% a year on average. The last full year, FY25, came in at ₹0.0 B. FY25 revenue was ₹0.0 B, +100.0% on the year before. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## How much of its sales does Zenas BioPharma keep? Zenas BioPharma, Inc.'s sales have fallen to very little: FY25 revenue was ₹0.0 B, against ₹0.1 B in FY23. On sales that small an operating margin is not a useful reading, so this section is left out until sales recover. ## Is Zenas BioPharma's profit turning into cash? Zenas BioPharma, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used ₹0.2 B of cash, against −₹0.4 B of profit. After ₹0.0 B of spending on assets, free cash was −₹0.2 B: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: it spends almost nothing on new assets, so the cash goes on running the business. The next section shows the spending figures. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## Where does Zenas BioPharma's cash go? Zenas BioPharma, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent ₹0.0 B on assets over the last 3 years. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: ₹0.0 B over the last 3 years. In short: almost nothing is being spent on new assets, so the cash goes on running the business. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## What is Zenas BioPharma's P/E ratio, and how does it compare with its own history? Zenas BioPharma, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. The P/E comes back here once profit turns positive. ## Is the Zenas BioPharma business getting better or worse? Zenas BioPharma, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Zenas BioPharma earn on its capital? Zenas BioPharma, Inc. earned a ROE of −156% in FY25. Its return on capital used (ROIC) is left out: on sales this small it reads −44%, a number that says nothing useful about the business. ## Does Zenas BioPharma have too much debt? Zenas BioPharma, Inc. has total debt of ₹0.3 B against shareholder equity of ₹0.2 B as of Jun 2026, so its debt is 1.21× its equity. Year by year, that ratio went from 0.03 in FY22 to 0.01 in FY25. Keep that borrowing in mind when reading the returns on this page. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## What is the Zenas BioPharma shareholding pattern? 27.9% of Zenas BioPharma, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 17.3 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Zenas BioPharma from balance-sheet trouble? For Zenas BioPharma, Inc., the Z-score is −0.60. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of −0.60 is inside the danger zone, so the balance sheet is a real risk. ## How does Zenas BioPharma rank in its industry? There is no score against its industry: Zenas BioPharma, Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Zenas BioPharma compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Zenas BioPharma in size? Zenas BioPharma is the 83rd largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 4 November 2026). Just above it: Vir Biotechnology, Inc., Mesoblast and Agios Pharmaceuticals, Inc. Just below it: Generate Biomedicines, Inc., Precigen, Inc. and Absci Corporation. ### Biotechnology companies close in size

1. [Vir Biotechnology, Inc.](https://www.sectoralpha.in/us/stocks/vir) $2 billion
2. [Mesoblast Limited](https://www.sectoralpha.in/us/stocks/meso) $1.9 billion
3. [Agios Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/agio) $1.9 billion
4. Zenas BioPharma, Inc. $1.9 billion
5. [Generate Biomedicines, Inc.](https://www.sectoralpha.in/us/stocks/genb) $1.8 billion
6. [Precigen, Inc.](https://www.sectoralpha.in/us/stocks/pgen) $1.8 billion
7. [Absci Corporation](https://www.sectoralpha.in/us/stocks/absi) $1.8 billion

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [The Andersons, Inc.](https://www.sectoralpha.in/us/stocks/ande) $1.9 billion · Food Distribution
2. [Brightstar Lottery PLC](https://www.sectoralpha.in/us/stocks/brsl) $1.9 billion · Gambling
3. Zenas BioPharma, Inc. $1.9 billion
4. [Nayax Ltd.](https://www.sectoralpha.in/us/stocks/nyax) $1.9 billion · Software - Infrastructure
5. [AMN Healthcare Services, Inc.](https://www.sectoralpha.in/us/stocks/amn) $1.8 billion · Medical Care Facilities

## What else do people ask about Zenas BioPharma? ### What were Zenas BioPharma's latest quarterly results? Zenas BioPharma, Inc. reported revenue of ₹0.0 B and a net loss of ₹0.1 B for the Jun 2026 quarter. The operating margin was −7,765.9% (as of 4 November 2026). ### What is Zenas BioPharma's market cap? Zenas BioPharma, Inc.'s market capitalisation is $1.9 B at a stock price of $28.46. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Zenas BioPharma performing? Zenas BioPharma, Inc.'s share price has been rising for 20 weeks. Over the past 13 weeks it has done worse than the S&P 500, for 5 weeks running. This describes what the data did, not a rating (as of 4 November 2026). ### Will Zenas BioPharma's stock price go up? This page does not forecast Zenas BioPharma, Inc.'s stock price. What it shows instead: the stock price is $28.46, and it has been rising for 20 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 4 November 2026). ### What could break the Zenas BioPharma story? Biggest thing to watch: the price has already been rising for 20 weeks, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Zenas BioPharma a stock worth studying right now? What the numbers show: Zenas BioPharma, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). This is research, not advice. We’re not SEBI-registered.